

RP00139

Leader in Biomolecular Solutions for Life Science



# Recombinant Human FAS/APO-1/CD95 Protein

Catalog No.: RP00139

Recombinant

## Sequence Information

Species	Gene ID	Swiss Prot
Human	355	P25445

### Tags

C-hFc&His

### Synonyms

ALPS1A;APO-1;APT1;CD95;FAS1;FASTM;TNFRSF6;FAS; ALPS1A; APO-1; APT1; CD95; FAS1; FASTM; TNFRSF6; Fas cell surface death receptor

## Product Information

Source	Purification
HEK293 cells	> 90% by SDS-PAGE.

### Endotoxin

< 0.1 EU/μg of the protein by LAL method.

### Formulation

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.

### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

## Contact



[www.abclonal.com](http://www.abclonal.com)

## Background

The protein is a member of the TNF-receptor superfamily. This receptor contains a death domain. It has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The interaction of this receptor with its ligand allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10. The autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, and leads to apoptosis. This receptor has been also shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is found to be involved in transducing the proliferating signals in normal diploid fibroblast and T cells. The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.

## Basic Information

### Description

Recombinant Human FAS/APO-1/CD95 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln26-Asn173) of human FAS/CD95/APO-1/TNFRSF6 (Accession #NP\_000034.1) fused with an Fc, 6×His tag at the C-terminus.


### Bio-Activity

1. Measured by its binding ability in a functional ELISA. Immobilized recombinant Human Fas Ligand at 2 μg/mL (100 μL/well) can bind recombinant Human FAS. The EC<sub>50</sub> of Human FAS is 6.23 ng/mL. 2. Measured by its ability to inhibit Fas Ligand-induced apoptosis of Jurkat Human acute T cell leukemia cells. The ED<sub>50</sub> for this effect is typically 16.5-66 ng/mL in the presence of 5 ng/mL Recombinant Human Fas Ligand.


### Storage

Store the lyophilized protein at -20°C to -80 °C for long term. After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week. Avoid repeated freeze/thaw cycles.


## Validation Data



Recombinant Human FAS/APO-1/CD95 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 50-70 kDa.



Immobilized recombinant Human Fas Ligand at 2 $\mu$ g/mL (100  $\mu$ L/well) can bind recombinant Human FAS, the EC<sub>50</sub> of Human FAS is 6.23 ng/mL.



Recombinant Human FAS inhibit Fas Ligand-induced apoptosis of Jurkat Human acute T cell leukemia cells. The ED<sub>50</sub> for this effect is typically 16.5-66 ng/mL in the presence of 5 ng/mL Recombinant Human Fas Ligand.